Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer
Clinical trial NCT03007992 · COMPLETED
Trial details
- NCT number
- NCT03007992
- Sponsor
- Johannes Gutenberg University Mainz
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-01
- Primary completion
- 2019-03-02
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.